Coagulation Analyzers Market Insights, Competitive Landscape and Market Forecast–2027
Coagulation Analyzers Market By Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents and Consumables), By Test Type (Fibrinogen Testing, Activated Clotting Time Testing (Act), D-Dimer Testing, Platelet Function Testing, Others), By Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), By End-User (Hospitals, Diagnostic Centers, and Others), and By Geography is anticipated to grow at a significant CAGR forecast till 2027 owing to rising prevalence of thromboembolytic disease, bleeding disorders and increase in the availability of more advanced products.
Global Coagulation Analyzers Market was valued at USD 4.41 billion in 2021, growing at a CAGR of 5.45% during the forecast period from 2022 to 2027, to reach USD 6.06 billion by 2027. The demand for Coagulation Analyzers is predominantly associated with the rising prevalence of thromboembolytic disease and bleeding disorders such as impaired liver function, hemophilia, and von Willebrand disease. Moreover, the increase in the availability of more advanced analyzers, growing awareness about these diseases and their management, rising geriatric population base are some of the factors likely to boost the Global Coagulation Analyzers Market during the forecast period.
Coagulation Analyzers Market Dynamics:
The Coagulation Analyzers Market has significantly increased owing to the fact that coagulation analysis allows for faster and efficient assessment of blood platelet levels, as well as determining the velocity of different concentrations.
According to the Centers for Disease Control and Prevention 2020, people with hemophilia have unique risk factors that may lead them to heart disease as their life expectancy increases, such as infusion of factor concentrates and infection with HIV. Owing to the growing burden of lifestyle-associated and chronic blood disorders across the globe, the Coagulation Analyzers market has been rising significantly. Similarly, as per Haemophilia Foundation Australia 2021, Haemophilia occurs in 1 in 6,000-10,000 males internationally. According to the same statistics, in Australia, there are more than 3,000 people diagnosed with varying degrees of severity of Haemophilia.
Another factor responsible for the growth of the Coagulation Analyzers market is the prevalence of von Willebrand disease (VWD). As per the Centers for Disease Control and Prevention 2021, VWD is the most common bleeding disorder, found in up to 1% of the US population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease.
Chronic blood disorders have a significant impact on the health and quality of life of patients and their families. They can cause pain, loss of normal functioning, depression, and anxiety, financial burden, long-term hospitalization, and even death. Therefore, to properly treat and manage chronic blood disorders like Haemophilia and VWD, Coagulation Analyzers devices are required. These devices help to detect clotting deficiencies, measure coagulation pathways speed, thrombolin levels and are also used to monitor the effects of drugs on whole blood. Since their use is quite extensive and offers wide applications in blood disorders, thus the demand for these devices will grow, which in turn is expected to drive the Global Coagulation Analyzers market.
It is estimated that up to 1% of the world’s population suffers from VWD, but because many people have only very mild symptoms, only a small number of them know they have it. Research has shown that as many as 9 out of 10 people with VWD have not been diagnosed, as per the World Federation of Hemophilia, 2021. Therefore, early detection using coagulation analyzers is very much important and will thereby promote the growth of the global Coagulation Analyzers market.
In addition, key players operating in the market are focusing on developing advanced technologically based Coagulation Analyzers devices and reagents. For instance, in March 2019, HORIBA Medical launched a new Yumizen GDDi 2 (D-Dimer) reagent kit in its hemostasis instrument range, which includes the compact Yumizen G200 coagulation analyzer. The kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). Thus, such development by players may help in contributing to patient management that will augment the demand for Global Coagulation Analyzers and will drive the market growth during the forecasted period from 2022-2027.
Coagulation Analyzers Market Segment Analysis:
Coagulation Analyzers Market by Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents and Consumables), by Test Type (Fibrinogen Testing, Activated Clotting Time Testing (ACT), D-Dimer Testing, Platelet Function Testing, Others), by Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), by End User (Hospitals, Diagnostic Centers, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Coagulation Analyzers product segment, the Automated Analyzers segment is anticipated to hold the largest market share. This is owing to the minimal manual interaction which drastically reduces the chances of infections, errors, rapid precision which ensures reproducibility, reduced personnel to do the task, and most importantly, a large number of samples that can be processed at the same time.
The advantages associated with automated coagulation analyzers are further increasing their demand, thereby driving the growth of the overall Coagulation Analyzers market.
Additionally, a new development in the product lines and new product launches are bolstering the segment growth of the Coagulation Analyzers market during the forecasted period.
North America is expected to dominate the overall Coagulation Analyzers Market:
North America is expected to dominate the overall Coagulation Analyzers market during the forecast period. This domination is owing to the rising prevalence of chronic blood diseases such as Hemophilia and von Willebrand disease. As per the National Hemophilia Foundation 2021, between 30,000- 33,000 people are living with hemophilia in the US.
Additionally, according to CDC 2020, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year in the United States. Thus, the burgeoning cases of diseases will contribute to the growth of the Coagulation Analyzers Market in the region as the demand will increase.
Further, in North America and at the global level the United States represents the largest market worldwide supported by increased awareness about rare diseases and rise in healthcare expenditure by the government owing to the research and development to improve the diagnostic rate and preventive care management among the patients.
Europe and Asia-Pacific region have the future potential growth for the Global Coagulation Analyzers market. This is owing to the rising burden of blood diseases in the European region countries and Asian countries. As per the Haemophilia Foundation Australia, 2021, more than 6,500 people in Australia have been diagnosed with a bleeding disorder.
According to the same statistics, more than 2,300 people have been diagnosed with VWD in Australia, but many more are thought to be undiagnosed. It affects both females and males from all racial backgrounds. Moreover, rising product launch and commercialization agreements among the key manufacturers and other companies are anticipated to boost the Coagulation Analyzers market. For instance, in July 2020, Sysmex launched next-generation fully automated blood coagulation analyzers CN-6000 and CN-3000 in the EMEA region. Such initiatives are anticipated to boost the Coagulation Analyzers Market.
Coagulation Analyzers Market Key Players:
Some of the key market players operating in the Coagulation Analyzers market include Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation among others.
Recent Developmental Activities in Coagulation Analyzers Market:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook